Compare FSFG & STXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FSFG | STXS |
|---|---|---|
| Founded | 2008 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 221.5M | 210.0M |
| IPO Year | 2008 | 2004 |
| Metric | FSFG | STXS |
|---|---|---|
| Price | $33.00 | $2.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $31.50 | $4.00 |
| AVG Volume (30 Days) | 12.4K | ★ 471.8K |
| Earning Date | 01-27-2026 | 11-11-2025 |
| Dividend Yield | ★ 1.94% | N/A |
| EPS Growth | ★ 67.68 | N/A |
| EPS | ★ 3.32 | N/A |
| Revenue | ★ $83,825,000.00 | $30,075,000.00 |
| Revenue This Year | N/A | $24.48 |
| Revenue Next Year | N/A | $29.98 |
| P/E Ratio | $9.93 | ★ N/A |
| Revenue Growth | ★ 23.11 | 19.62 |
| 52 Week Low | $21.63 | $1.54 |
| 52 Week High | $33.27 | $3.59 |
| Indicator | FSFG | STXS |
|---|---|---|
| Relative Strength Index (RSI) | 69.74 | 44.67 |
| Support Level | $31.45 | $2.34 |
| Resistance Level | $33.27 | $2.44 |
| Average True Range (ATR) | 0.42 | 0.10 |
| MACD | 0.20 | 0.03 |
| Stochastic Oscillator | 90.00 | 56.66 |
First Savings Financial Group Inc provides various banking services to individuals and business customers in southern Indiana. The bank accepts deposits from the general public & uses those funds, along with other borrowings, mainly to originate a residential mortgage, commercial mortgage, construction, commercial business, & consumer loans, and to a lesser extent, to invest in mortgage-backed securities and other debt securities. The company conducts lending and deposit activities mainly with individuals and small businesses in its market area. The bank operates in two segments: core banking, which accounts for the majority of revenue, and SBA lending.
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.